Traduction de «well as productivity gains from forward » (Néerlandais → Français) :

Operating income advanced 32% to USD 9.0 billion due to the solid business expansion as well as productivity gains from Forward, the Group’s efficiency initiative that is freeing up resources for investments in innovation and expansion in high-growth markets.
Le résultat opérationnel a progressé de 32% à USD 9,0 milliards grâce à la solide expansion des activités et à des gains de productivité dégagés par Forward, le projet visant à accroître l’efficience du Groupe.

Core operating income, which excludes exceptional items and amortization of intangible assets in both periods, grew 11% to USD 11.4 billion on improvements in Pharmaceuticals and Vaccines and Diagnostics as well as productivity gains in all divisions.
Le résultat opérationnel «core», qui exclut les éléments exceptionnels et l’amortissement d’immobilisations incorporelles dans les deux périodes, a progressé de 11% à USD 11,4 milliards, à la suite d’améliorations dans les divisions Pharmaceuticals et Vaccins et Diagnostic ainsi que de gains de productivité dans toutes les divisions.

Consumer Health continuing operations: +124% to USD 190 million Excluding USD 97 million of Forward restructuring charges in 2007, operating income rose 4% mainly on strong underlying growth in CIBA Vision and productivity gains across the businesses, but was impacted by negative currency movements.
Consumer Health, activités poursuivies: +124% à USD 190 millions Hors charges de restructuration Forward d'USD 97 millions en 2007, le résultat opérationnel a progressé de 4%, essentiellement en raison d’une forte croissance sousjacente de CIBA Vision et de gains de productivité dans toutes les activités, mais il a subi l'effet de taux de change défavorables.

Consumer Health continuing operations: +29% to USD 1.0 billion Robust growth in operating income outpaced net sales thanks to the business expansion, particularly in CIBA Vision, and Forward-related productivity gains.
Consumer Health, activités poursuivies: +29% à USD 1,0 milliard La croissance robuste du résultat opérationnel a surpassé celle du chiffre d’affaires net grâce à l’expansion des activités, en particulier à CIBA Vision, et à des gains de productivité liés à Forward.

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

The double-digit sales expansion and productivity gains of more than USD 700 million in the 2009 period fueled operating income growth and enabled significant investments in new product launches as well as accelerated investments in Oncology projects, particularly Afinitor, and targeted emerging markets such as China.
La hausse à deux chiffres des ventes et des gains de productivité de plus d’USD 700 millions, au cours des neuf premiers mois de l’année, ont alimenté la croissance du résultat opérationnel. Celle-ci a permis de procéder à des investissements importants dans le lancement de nouveaux produits et d’accélérer les investissements dans des projets d’Oncologie, en particulier Afinitor, et dans des marchés émergents ciblés comme la Chine.

Significant productivity gains in production, marketing and selling, and administrative areas helped to finance R&D projects involving many novel and potentially first-in-class compounds as well as rapid expansion in high-growth markets.
Des gains de productivité importants dans la production, le marketing et la vente ainsi que dans l’administration ont aidé à financer des projets de R&D impliquant de nombreuses molécules nouvelles et potentiellement premières de leur classe ainsi qu’une expansion rapide dans des marchés en pleine croissance.

The increase is attributable to higher contributions from the Alcon and Roche investments due to exceptional charges incurred in the prior year period as well as the revaluation gain to the currently estimated fair value of the initial 25% Alcon interest acquired on July 7, 2008.
Cette hausse est attribuable à une hausse des contributions provenant des investissements dans Alcon et Roche due à des charges exceptionnelles au cours de la même période de 2009 ainsi qu’à une estimation du gain de réévaluation à la juste valeur de la participation initiale de 25% dans Alcon acquise le 7 juillet 2008.

As for D-glucuronolactone, the group believes that this concerns a normal human metabolite deriving from glucose, which does not involve a structural risk with regard to mutagenicity or carcinogenicity. It also holds that both this component as well as its hydrolysis product, glucuronic acid, are endogenous metabolites in humans and other mammals, that they are naturally present in various food sources and that they are quickly metabolised into innocuous products and excreted.
Pour la D-glucuronolactone, le groupe considère qu’il s’agit d’un métabolite humain normal provenant du glucose qui ne présente pas de risque structural en termes de mutagénicité ou de carcinogénicité, que pour ce composant, comme pour son produit d’hydrolyse, l’acide glucuronique, il s’agit de métabolites endogènes chez l’homme et les autres mammifères, qu’ils se trouvent à l’état naturel dans diverses sources alimentaires et qu’ils sont rapidement métabolisés en produits sans danger et excrétés.